Published in J Virol on July 01, 1991
Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans. J Virol (1998) 3.11
Differences in CD4 dependence for infectivity of laboratory-adapted and primary patient isolates of human immunodeficiency virus type 1. J Virol (1994) 2.51
Inhibition of virus attachment to CD4+ target cells is a major mechanism of T cell line-adapted HIV-1 neutralization. J Exp Med (1997) 2.31
Target cell-specific determinants of membrane fusion within the human immunodeficiency virus type 1 gp120 third variable region and gp41 amino terminus. J Virol (1992) 2.12
Nef does not affect the efficiency of human immunodeficiency virus type 1 fusion with target cells. J Virol (2003) 1.72
Human immunodeficiency virus type 1 replication in the absence of integrase-mediated dna recombination: definition of permissive and nonpermissive T-cell lines. J Virol (2001) 1.63
Human immunodeficiency virus type 1 DNA synthesis, integration, and efficient viral replication in growth-arrested T cells. J Virol (1993) 1.57
A putative receptor for Venezuelan equine encephalitis virus from mosquito cells. J Virol (1996) 1.56
Two amino acid substitutions within the capsid are coordinately required for acquisition of fibrotropism by the lymphotropic strain of minute virus of mice. J Virol (1992) 1.51
CD8+ T cell-mediated suppressive activity inhibits HIV-1 after virus entry with kinetics indicating effects on virus gene expression. Proc Natl Acad Sci U S A (2000) 1.35
Tumor necrosis factor alpha inhibits entry of human immunodeficiency virus type 1 into primary human macrophages: a selective role for the 75-kilodalton receptor. J Virol (1996) 1.07
Human immunodeficiency virus type 1 entry into T cells: more-rapid escape from an anti-V3 loop than from an antireceptor antibody. J Virol (1992) 1.04
T-cell activation influences initial DNA synthesis of simian immunodeficiency virus in resting T lymphocytes from macaques. J Virol (1993) 1.03
Replication of patient isolates of human immunodeficiency virus type 1 in T cells: a spectrum of rates and efficiencies of entry. Proc Natl Acad Sci U S A (1992) 1.02
Human immunodeficiency virus type 1 infection of the brain. Clin Microbiol Rev (1993) 0.94
Human plasma enhances the infectivity of primary human immunodeficiency virus type 1 isolates in peripheral blood mononuclear cells and monocyte-derived macrophages. J Virol (1995) 0.89
Initiation of human immunodeficiency virus type 1 (HIV-1) transcription is inhibited by noncytolytic CD8 suppression. Open Virol J (2007) 0.85
Single-Cell and Single-Cycle Analysis of HIV-1 Replication. PLoS Pathog (2015) 0.80
Biologically-directed modeling reflects cytolytic clearance of SIV-infected cells in vivo in macaques. PLoS One (2012) 0.78
HIV-1 gag cytotoxic T lymphocyte epitopes vary in presentation kinetics relative to HLA class I downregulation. J Virol (2013) 0.77
Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol (1986) 37.70
Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science (1984) 33.32
The role of mononuclear phagocytes in HTLV-III/LAV infection. Science (1986) 17.33
Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science (1987) 12.77
Biologic features of HIV-1 that correlate with virulence in the host. Science (1988) 9.06
Characterization of a continuous T-cell line susceptible to the cytopathic effects of the acquired immunodeficiency syndrome (AIDS)-associated retrovirus. Proc Natl Acad Sci U S A (1985) 8.53
Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides. Proc Natl Acad Sci U S A (1986) 6.63
The role of T3 surface molecules in the activation of human T cells: a two-stimulus requirement for IL 2 production reflects events occurring at a pre-translational level. J Immunol (1984) 5.80
Activation of the HIV-1 LTR by T cell mitogens and the trans-activator protein of HTLV-I. Science (1987) 5.22
Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates. J Virol (1988) 4.96
Epitopes of the CD4 antigen and HIV infection. Science (1986) 4.50
Restricted expression of human T-cell leukemia--lymphoma virus (HTLV) in transformed human umbilical cord blood lymphocytes. Virology (1983) 4.11
Human immunodeficiency virus infection of T cells and monocytes proceeds via receptor-mediated endocytosis. J Cell Biol (1988) 2.80
Differences in cytopathogenicity and host cell range among infectious molecular clones of human immunodeficiency virus type 1 simultaneously isolated from an individual. J Virol (1988) 2.24
A major mechanism of human immunodeficiency virus-induced cell killing does not involve cell fusion. J Virol (1987) 2.14
Human immunodeficiency virus type 1 T-cell tropism is determined by events prior to provirus formation. J Virol (1990) 2.11
Accumulation of human immunodeficiency virus type 1 DNA in T cells: results of multiple infection events. J Virol (1990) 1.78
Factors affecting cellular tropism of human immunodeficiency virus. J Virol (1990) 1.72
Internalization and recycling of CD4 transfected into HeLa and NIH3T3 cells. EMBO J (1989) 1.53
Expression of the complete human T-cell leukemia virus type I pX coding sequence as a functional protein in Escherichia coli. Proc Natl Acad Sci U S A (1986) 1.41
Interaction of a noncytopathic human immunodeficiency virus type 1 (HIV-1) with target cells: efficient virus entry followed by delayed expression of its RNA and protein. Virology (1990) 1.33
Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science (2001) 9.09
Avian leukosis virus-induced tumors have common proviral integration sites and synthesize discrete new RNAs: oncogenesis by promoter insertion. Cell (1981) 8.69
DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci U S A (1993) 4.49
Proteins of Rous sarcoma virus. Virology (1968) 3.84
DNA in uninfected and virus-infected cells complementary to avian tumor virus RNA. Proc Natl Acad Sci U S A (1971) 3.25
Acceptor sites for retroviral integrations map near DNase I-hypersensitive sites in chromatin. J Virol (1986) 3.21
At least two regions of the viral genome determine the oncogenic potential of avian leukosis viruses. Proc Natl Acad Sci U S A (1982) 2.84
Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J Immunol (1997) 2.69
Isolation and characterization of proteins from Rous sarcoma virus. Virology (1971) 2.66
DNA polymerase in defective Rous sarcoma virus. Virology (1971) 2.56
Heterogeneity of genetic loci in chickens: analysis of endogenous viral and nonviral genes by cleavage of DNA with restriction endonucleases. Cell (1979) 2.55
C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge. Nat Immunol (2000) 2.49
Tumor virus RNA's. Proc Natl Acad Sci U S A (1967) 2.18
A major mechanism of human immunodeficiency virus-induced cell killing does not involve cell fusion. J Virol (1987) 2.14
Isolation of noninfectious particles containing Rous sarcoma virus RNA from the medium of Rous sarcoma virus-transformed nonproducer cells. Proc Natl Acad Sci U S A (1967) 2.13
Unexpectedly high levels of HIV-1 RNA and protein synthesis in a cytocidal infection. Science (1988) 2.12
Patterns of proviral insertion and deletion in avian leukosis virus-induced lymphomas. J Virol (1986) 1.93
Host Susceptibility to endogenous viruses: defective, glycoprotein-expressing proviruses interfere with infections. J Virol (1981) 1.81
Subgroup-E avian-leukosis-virus-associated disease in chickens. Cold Spring Harb Symp Quant Biol (1980) 1.79
Accumulation of human immunodeficiency virus type 1 DNA in T cells: results of multiple infection events. J Virol (1990) 1.78
Intracellular restriction on the growth of induced subgroup E avian type C viruses in chicken cells. J Virol (1976) 1.76
Variation in avian retrovirus genomes. Ann N Y Acad Sci (1980) 1.75
Simian immunodeficiency virus DNA vaccine trial in macaques. J Virol (1996) 1.71
Production of unique C-type viruses by chicken cells grown in bromodeoxyuridine. Virology (1976) 1.70
High-frequency transduction of c-erbB in avian leukosis virus-induced erythroblastosis. J Virol (1985) 1.69
Ten genetic loci in the chicken that contain structural genes for endogenous avian leukosis viruses. Cold Spring Harb Symp Quant Biol (1980) 1.63
Use of DNAs expressing HIV-1 Env and noninfectious HIV-1 particles to raise antibody responses in mice. Virology (1995) 1.59
Inheritance and expression of chicken genes that are related to avian leukosis sarcoma virus genes. Curr Top Microbiol Immunol (1978) 1.54
Expression of endogenous ALV antigens and susceptibility to subgroup E ALV in three strains of chickens (endogenous avian C-type virus). Virology (1976) 1.52
Differences in sequences encoding the carboxyl-terminal domain of the epidermal growth factor receptor correlate with differences in the disease potential of viral erbB genes. Proc Natl Acad Sci U S A (1986) 1.52
Role of methylation in the induced and spontaneous expression of the avian endogenous virus ev-1: DNA structure and gene products. Mol Cell Biol (1982) 1.48
Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults. AIDS Res Hum Retroviruses (2006) 1.47
The dominant role of bone marrow-derived cells in CTL induction following plasmid DNA immunization at different sites. J Immunol (1997) 1.46
Differential dependence on target site tissue for gene gun and intramuscular DNA immunizations. J Immunol (1997) 1.45
Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions. AIDS Res Hum Retroviruses (1998) 1.41
Apoptosis-mediated enhancement of DNA-raised immune responses by mutant caspases. Nat Biotechnol (2001) 1.39
Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting. J Virol (1998) 1.39
Genomes of endogenous and exogenous avian retroviruses. Virology (1983) 1.33
Simian immunodeficiency virus-specific cytotoxic T-lymphocyte induction through DNA vaccination of rhesus monkeys. J Virol (1996) 1.29
Inhibition of growth of uninfected and rous sarcoma virus-infected chick-embryo fibroblasts by rifampicin. J Natl Cancer Inst (1971) 1.27
Protective CTL-dependent immunity and enhanced immunopathology in mice immunized by particle bombardment with DNA encoding an internal virion protein. J Immunol (1995) 1.27
Molecular mechanisms of action of ribavirin. Rev Infect Dis (1991) 1.26
Long terminal repeat (LTR) sequences, env, and a region near the 5' LTR influence the pathogenic potential of recombinants between Rous-associated virus types 0 and 1. J Virol (1988) 1.25
Influence of env and long terminal repeat sequences on the tissue tropism of avian leukosis viruses. J Virol (1988) 1.24
Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates. Mol Med (1999) 1.22
Induction of angiosarcoma by a c-erbB transducing virus. J Virol (1985) 1.22
Gs, an allele of chickens for endogenous avian leukosis viral antigens, segregates with ev 3, a genetic locus that contains structural genes for virus. J Virol (1979) 1.18
Cross-protection among lethal H5N2 influenza viruses induced by DNA vaccine to the hemagglutinin. J Virol (1997) 1.12
Avian leukosis virus-induced osteopetrosis is associated with the persistent synthesis of viral DNA. Virology (1985) 1.12
Protection against rotavirus infections by DNA vaccination. J Infect Dis (1996) 1.12
Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting. Virology (1997) 1.11
Sequences in the gag-pol-5'env region of avian leukosis viruses confer the ability to induce osteopetrosis. Virology (1985) 1.10
Enhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNA vaccination with gp120-C3d fusion proteins. AIDS Res Hum Retroviruses (2001) 1.09
Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques. J Virol (2001) 1.09
Sequences outside of the long terminal repeat determine the lymphomogenic potential of Rous-associated virus type 1. J Virol (1985) 1.08
C3d enhancement of neutralizing antibodies to measles hemagglutinin. Vaccine (2001) 1.08
Use of DNA encoding influenza hemagglutinin as an avian influenza vaccine. DNA Cell Biol (1993) 1.07
Context-dependent role of human immunodeficiency virus type 1 auxiliary genes in the establishment of chronic virus producers. J Virol (1993) 1.06
Proteins of avian tumor viruses with different coat antigens. J Virol (1970) 1.06
Dsi-1, a region with frequent proviral insertions in Moloney murine leukemia virus-induced rat thymomas. J Virol (1987) 1.05
Studies on antibody responses following neonatal immunization with influenza hemagglutinin DNA or protein. Virology (1999) 1.05
Human immunodeficiency virus type 1 entry into T cells: more-rapid escape from an anti-V3 loop than from an antireceptor antibody. J Virol (1992) 1.04
Sequences near the 5' long terminal repeat of avian leukosis viruses determine the ability to induce osteopetrosis. J Virol (1986) 1.04
Replication of patient isolates of human immunodeficiency virus type 1 in T cells: a spectrum of rates and efficiencies of entry. Proc Natl Acad Sci U S A (1992) 1.02
DNA vaccines: a novel approach to immunization. Int J Immunopharmacol (1995) 1.00
HIV-1 Env glycoproteins from two series of primary isolates: replication phenotype and immunogenicity. Virology (1997) 1.00
Retrovirus-expressed hemagglutinin protects against lethal influenza virus infections. J Virol (1988) 0.99
Replication of Rous sarcoma virus in synchronized cells. J Gen Virol (1970) 0.97
Low freqeuncy production of recombinant subgroup E avian leukosis viruses by uninfected V-15B chicken cells. Virology (1979) 0.96
Protective immunity induced by rotavirus DNA vaccines. Vaccine (1997) 0.96
Antibody-forming cell response to virus challenge in mice immunized with DNA encoding the influenza virus hemagglutinin. J Virol (1995) 0.95
DNA prime/protein boost vaccine strategy in neonatal macaques against simian human immunodeficiency virus. J Med Primatol (2002) 0.90
Neutralizing antibody responses in Africa green monkeys naturally infected with simian immunodeficiency virus (SIVagm). J Med Primatol (1999) 0.89
Susceptibility to erbB-induced erythroblastosis is a dominant trait of 151 chickens. J Virol (1985) 0.88
DNA vaccines for influenza virus: differential effects of maternal antibody on immune responses to hemagglutinin and nucleoprotein. J Virol (2000) 0.88
V-15B, an allele of chickens for the production of a noninfectious avian leukosis virus. Virology (1979) 0.88
DNA vaccines: a review of developments. BioDrugs (1997) 0.87
Retroviruses and cancer. Rev Infect Dis (1983) 0.87
DNA immunization: effect of secretion of DNA-expressed hemagglutinins on antibody responses. Vaccine (1999) 0.86
Heterologous neutralizing antibody induction in a simian-human immunodeficiency virus primate model: lack of original antigenic sin. J Infect Dis (2001) 0.86
Role of different lymphoid tissues in the initiation and maintenance of DNA-raised antibody responses to the influenza virus H1 glycoprotein. J Virol (1996) 0.85
Increased oncogenic potential of ErbB is associated with the loss of a COOH-terminal domain serine phosphorylation site. J Biol Chem (1992) 0.84
Endogenous virus expression in chicken lines maintained at the Regional Poultry Research Laboratory. Virology (1979) 0.84
New findings on the congenital transmission of avian leukosis viruses. Science (1984) 0.84
Protein tyrosine kinase activities of the epidermal growth factor receptor and ErbB proteins: correlation of oncogenic activation with altered kinetics. Mol Cell Biol (1992) 0.83
Influence of avian leukosis viral sequences on transmission to the egg and embryo. Virology (1989) 0.81
Basic mechanisms of DNA-raised antibody responses to intramuscular and gene gun immunizations. DNA Cell Biol (2000) 0.81
Th1 genetic adjuvants modulate immune responses in neonates. Vaccine (2001) 0.81
Infrequent involvement of c-fos in avian leukosis virus-induced nephroblastoma. J Virol (1990) 0.81
Identification of a mouse protein homologous to the human CD6 T cell surface protein and sequence of the corresponding cDNA. J Immunol (1995) 0.81
Induction of renal adenocarcinoma by a nonmutated erbB oncogene. J Virol (1993) 0.80
DNA vaccines against rotavirus infections. Arch Virol Suppl (1996) 0.80
Assessment of retrovirus-expressed nucleoprotein as a vaccine against lethal influenza virus infections of chickens. Avian Dis (1992) 0.80
Early studies on DNA-based immunizations for measles virus. Vaccine (1997) 0.79
Mucosal immunization with DNA encoding influenza hemagglutinin. Vaccine (1997) 0.78
Role of RAV-0 genes in the permissive replication of subgroup E avian leukosis viruses on line 15Bev1 CEF. Virology (1988) 0.78